Evidence map›Paper›PMID 37175540›Full record

ReviewInternational journal of molecular sciences2023

Amino-Pyrazoles in Medicinal Chemistry: A Review.

Matteo Lusardi, Andrea Spallarossa, Chiara Brullo

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. SwitchingInternational journal of molecular sciences · 2025
    Article
  9. Article
  10. Anticancer Activity ofBiomolecules · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Anticancer Effects of the Novel Pyrazolyl-Urea GeGe-3.International journal of molecular sciences · 2024
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Matteo LusardiDepartment of Pharmacy (DIFAR), Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy.ORCID 0000-0002-7003-7891
Andrea SpallarossaDepartment of Pharmacy (DIFAR), Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy.ORCID 0000-0002-3360-7146
Chiara BrulloDepartment of Pharmacy (DIFAR), Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy.ORCID 0000-0002-2575-7726
University of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A pyrazole nucleus is an easy-to-prepare scaffold with large therapeutic potential. Consequently, the search for new pyrazole-based compounds is of great interest to the academic community as well as industry. In the last ten years, a large number of papers and reviews on the design, synthesis, and biological evaluation of different classes of pyrazoles and many pyrazole-containing compounds have been published. However, an overview of pyrazole derivatives bearing a free amino group at the 3, 4, or 5 position (namely, 3-aminopyrazoles, 4-aminopyrazoles, and 5-aminopyrazoles, respectively) and their biological properties is still missing, despite the fact that aminopyrazoles are advantageous frameworks able to provide useful ligands for receptors or enzymes, such as p38MAPK, and different kinases, COX and others, as well as targets important for bacterial and virus infections. With the aim to fill this gap, the present review focuses on aminopyrazole-based compounds studied as active agents in different therapeutic areas, with particular attention on the design and structure-activity relationships defined by each class of compounds. In particular, the most relevant results have been obtained for anticancer/anti-inflammatory compounds, as the recent approval of Pirtobrutinib demonstrates. The data reported here are collected from different databases (Scifinder, Web of Science, Scopus, Google Scholar, and Pubmed) using "aminopyrazole" as the keyword.

Indexed as

Anti-Inflammatory AgentsChemistry, PharmaceuticalPyrazolesStructure-Activity RelationshipAnti-Inflammatory AgentspirtobrutinibPyrazolesaminopyrazolebiological propertiesmedicinal chemistryp38MAPKpyrazole

Identifiers

PMID37175540
PMCPMC10177828
OpenAlexW4367053042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.